Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Both MNCs, Local Korean Pharmas Under Korean Government Surveillance For IP Protection

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In its first examination into intellectual property rights related to deals among pharma companies operating in Korea, South Korea's Fair Trade Commission is now accepting complaints and opinions from 30 leading multinational companies and 18 local Korean companies

You may also be interested in...



Korea's Trade Commission Offers Payment To Whistleblowers Reporting Rebates

SEOUL - In its latest anti-rebate move, South Korea's Fair Trade Commission is offering up to KRW100 million ($82,440) to whistleblowers who uncover illegal rebates offered by pharma companies for sales of their products to hospitals. The new punitive system took effect June 17

OECD Recommends Changes in Korea's Healthcare System In Its First Survey Of Korea's Pharma Sector

SEOUL - OECD has recommended a set of changes - some of them already pursued by the South Korean government - to get South Korea's healthcare system working more efficiently to curtail rapid increases in healthcare spending

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel